Table 4:

Overall survival and recurrence/progression-free survival—survival rates and log-rank tests.

	n	n eventsa	1-Year survival	3-Year survival	5-Year survival	P-Value
OS	58	13	0.95	0.83	0.77
Cisplatin dose
Low	30	7	1.00	0.91	0.81	0.537
High	28	6	0.89	0.74	0.74
Chemotherapeutical agent
Cisplatin alone	38	9	1.00	0.86	0.77	0.953
Cisplatin + doxorubicin	20	4	0.84	0.78	0.78
Resection status
R0/1	49	9	0.96	0.85	0.85	0.170
R2	9	4	0.89	0.76	0.51
Postoperative renal insufficiency
No	54	12	0.94	0.84	0.77	0.988
Yes	4	1	1.00	0.75	0.75
Histological subtypeb
Thymoma	42	4	1.00	0.94	0.94	<0.001
Thymic carcinoma	15	8	0.79	0.61	0.41
Additive chemotherapy
No	33	10	0.91	0.71	0.71	0.053
Yes	25	3	1.00	1.00	0.84
RFS/PFS	58	34	0.89	0.54	0.44
Cisplatin dose
Low	30	23	0.97	0.43	0.31	0.110
High	28	11	0.81	0.68	0.62
Chemotherapeutical agent
Cisplatin alone	38	24	0.97	0.46	0.43	0.954
Cisplatin + doxorubicin	20	10	0.73	0.61	0.45
Resection status
R0/1	49	27	0.89	0.55	0.45	0.886
R2	9	7	0.89	0.51	0.38
Postoperative renal insufficiency
No	54	33	0.90	0.52	0.42	0.129
Yes	4	1	1.00	0.75	0.75
Histological subtypeb
Thymoma	42	20	0.97	0.68	0.57	0.001
Thymic carcinoma	15	13	0.65	0.22	0.14
Additive chemotherapy
No	33	16	0.84	0.54	0.49	0.607
Yes	25	18	0.96	0.54	0.39

^aIn OS analyses, events are defined as deaths from any cause. In RFS/PFS analyses, events are defined as 1st tumour recurrence or progression or death from any cause.

^bOne patient was excluded due to atypical carcinoid of the thymus.

OS: overall survival; PFS: progression-free survival; RFS: recurrence-free survival.

Bold represents Statistical significant.